Shares of Myriad Genetics Inc. fell 5 percent in Monday trading on news that the company's Act-Earli-AD trial, a pivotal 18-month Phase III study of Flurizan (tarenflurbil) in patients with mild Alzheimer's disease (AD), did not achieve statistical significance on either of its primary endpoints - cognition and activities of daily living. (BioWorld Today)
Women suffering from irritable bowel syndrome (IBS) found something to settle their stomachs in May when the FDA cleared the way for Amitiza, a chloride channel activator that alleviates constipation, but analysts and biotechs alike contend that there's more room for competitors in the space. (BioWorld Financial Watch)
Alnylam Pharmaceuticals Inc. inked its third significant deal of the year, signing an exclusive alliance agreement to develop and commercialize ALN-RSV01, its lead RNAi therapeutic for the treatment of respiratory syncytial virus (RSV) infection, with Japanese firm Kyowa Hakko Kogyo Co. Ltd. (BioWorld Today)
